AaiPharma “Unusual Sales” May Prompt Subpoenas; CEO Steps Down
An investigation into sales of aaiPharma products may result in subpoenas from the Securities & Exchange Commission and the U.S. Attorney's Office, the company said
You may also be interested in...
AaiPharma may delay filing its Form 10-K while an independent committee investigates "unusual sales" for the bronchodilatorBrethine and pain agent Darvocet...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials